A	B	C
1	Main
2		Brand	TAK-999, ARO-AAT
3		Generic	fazirsiran
4		Indication	alpha-1 antitrypsin deficiency (AATD)
5		Competition	NTLA IND in 2H23
6		Economics	Takeda licensed for $300m upfront, US 50-50 and 20-25% Ex-US royalties
7		Clinical Trials
8
9
10			Phase III TAK-999-3001 n=160 AATD liver
11			PE: METAVIR stage at Week 106
12
13			Phase II "SEQUOIA"
14			Week 48 reductions of serum Z-AAT of 74%, 89% and 94% 25mg, 100mg, 200mg vs 0% for placebo
15			50% achieved 1 point in METAVIR, but 38% also improved in placebo??